loading
Schlusskurs vom Vortag:
$17.86
Offen:
$17.96
24-Stunden-Volumen:
58,849
Relative Volume:
0.03
Marktkapitalisierung:
$1.55B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-4.0409
EPS:
-4.52
Netto-Cashflow:
$-369.41M
1W Leistung:
-1.42%
1M Leistung:
+0.59%
6M Leistung:
+175.45%
1J Leistung:
+222.26%
1-Tages-Spanne:
Value
$17.89
$18.36
1-Wochen-Bereich:
Value
$16.86
$18.55
52-Wochen-Spanne:
Value
$5.12
$20.33

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name
Firmenname
Travere Therapeutics Inc
Name
Telefon
888-969-7879
Name
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Name
Mitarbeiter
380
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
TVTX's Discussions on Twitter

Vergleichen Sie TVTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
TVTX 18.36 1.55B 203.45M -351.45M -369.41M -4.52
VRTX 447.53 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.03 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.31 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.73 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.47 24.49B 3.30B -501.07M 1.03B 11.54

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-03-27 Herabstufung Guggenheim Buy → Neutral
2023-12-05 Hochstufung Citigroup Neutral → Buy
2023-11-20 Eingeleitet Citigroup Neutral
2023-09-22 Herabstufung Wells Fargo Overweight → Equal Weight
2023-09-21 Herabstufung William Blair Outperform → Mkt Perform
2023-09-06 Fortgesetzt Evercore ISI Outperform
2023-07-21 Eingeleitet JP Morgan Overweight
2023-06-07 Fortgesetzt Piper Sandler Neutral
2023-05-22 Eingeleitet TD Cowen Outperform
2023-05-05 Hochstufung Bryan Garnier Sell → Neutral
2023-03-01 Eingeleitet Guggenheim Buy
2023-02-21 Hochstufung Wedbush Neutral → Outperform
2022-12-14 Eingeleitet Stifel Hold
2022-12-05 Eingeleitet Wells Fargo Overweight
2022-09-21 Eingeleitet Bryan Garnier Sell
2022-07-14 Fortgesetzt Canaccord Genuity Buy
2022-03-31 Eingeleitet Piper Sandler Overweight
2022-02-28 Eingeleitet H.C. Wainwright Buy
2021-05-26 Herabstufung Wedbush Outperform → Neutral
Alle ansehen

Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten

pulisher
03:38 AM

Oppenheimer & Co. Inc. Acquires New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

03:38 AM
pulisher
Nov 19, 2024

Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level - Yahoo! Voices

Nov 19, 2024
pulisher
Nov 18, 2024

Travere: Q3 Earnings Snapshot - AOL

Nov 18, 2024
pulisher
Nov 18, 2024

Los Angeles Capital Management LLC Has $391,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

When (TVTX) Moves Investors should Listen - Stock Traders Daily

Nov 15, 2024
pulisher
Nov 15, 2024

Exploring Three High Growth Tech Stocks in the United States - Simply Wall St

Nov 15, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere The - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Awards 24,400 RSUs to New Employees in Talent Acquisition Push | TVTX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - The Globe and Mail

Nov 13, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Completes $143.8 Million Public Offering - Marketscreener.com

Nov 13, 2024
pulisher
Nov 12, 2024

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - The Manila Times

Nov 12, 2024
pulisher
Nov 11, 2024

3 Under-the-Radar Healthcare Companies - sharewise

Nov 11, 2024
pulisher
Nov 11, 2024

3 Under-the-Radar Healthcare Companies to Watch - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Unitedhealth Group Inc (UNH-N) QuotePress Release - The Globe and Mail

Nov 11, 2024
pulisher
Nov 10, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Nov 10, 2024
pulisher
Nov 09, 2024

Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month HighHere's What Happened - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

TVTX stock soars to 52-week high, hits $19.29 amid robust gains - Investing.com India

Nov 08, 2024
pulisher
Nov 08, 2024

Latham & Watkins Advises on Travere Therapeutics’ Public Offering of Common Stock - Latham & Watkins LLP

Nov 08, 2024
pulisher
Nov 08, 2024

Travere Therapeutics plans public stock offering By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics plans public stock offering - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Launches Public Stock Offering, Led by Jefferies & Leerink | TVTX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

Travere Therapeutics' SWOT analysis: filspari approval boosts rare disease stock outlook - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024
pulisher
Nov 03, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat

Nov 03, 2024
pulisher
Nov 03, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

TVTXTravere Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Scotiabank Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024

Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):